The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis

The JAK2 c.1849G>T (p.V617F) mutation leads to constitutive activation of Janus kinase (JAK)2 and contributes to dysregulated JAK signaling in myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Trea...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Deininger, Michael, Radich, Jerald, Burn, Timothy C., Huber, Reid, Paranagama, Dilan, Verstovsek, Srdan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2015
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4582331/
https://ncbi.nlm.nih.gov/pubmed/26228487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-635235
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg